



Too much iron: A masked foe for leukemias

Eolia Brissot, Delphine G Bernard, Olivier Loréal, Pierre Brissot,
Marie-Bérengère Troadec

► To cite this version:

Eolia Brissot, Delphine G Bernard, Olivier Loréal, Pierre Brissot, Marie-Bérengère Troadec. Too much iron: A masked foe for leukemias. *Blood Reviews*, 2020, 39, pp.100617. 10.1016/j.blre.2019.100617 . hal-02472239

HAL Id: hal-02472239

<https://univ-rennes.hal.science/hal-02472239>

Submitted on 23 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Too much iron: a masked foe for leukemias

BRISSOT Eolia*

Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France ;

Sorbonne Universités, UPMC Univ. Paris 06, AP-HP, Centre de recherche Saint-Antoine, UMR-S938, Paris, France

eolia.brissot@aphp.fr

Tel.: +33 1 49 28 31 93

BERNARD Delphine

Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France

delphine.bernard@univ-brest.fr

Tel.: +33 2 98 01 60 00

LORÉAL Olivier

Institut NuMeCan, Inserm U-1241, Univ Rennes 1, Rennes, France

olivier.loreal@univ-rennes1.fr

Tel.: +33 2 99 54 37 37

BRISSOT Pierre

Institut NuMeCan, Inserm U-1241, Univ Rennes 1, Rennes, France

pierre.brissot@gmail.com

Tel.: +33 2 99 54 37 37

TROADEC Marie-Bérengère*

Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France

CHRU Brest, Service de génétique, Unité de cytogénétique, France

marie-berengere.troadec@univ-brest.fr

Tel.: +33 2 98 01 64 55

32 * CORRESPONDING AUTHORS:

33 E-mail addresses:

34 eolia.brissot@aphp.fr (E. Brissot)

35 marie-berengere.troadec@univ-brest.fr (M-B. Troadec)

36

37

39 The role of iron in non-erythroid hematopoietic lineages and its implication in hemato-oncogenesis are
40 still debated. Iron exerts an important role on hematopoietic stem cell transformation and on mature
41 white blood cell differentiation. Iron acts experimentally as an oncogenic cofactor but its exact role in the
42 transformation of the myelodysplastic syndrome into leukemia continues to be discussed. Body iron
43 overload frequently develops mainly as the result of multiple erythrocyte transfusions in patients with
44 leukemia or myelodysplastic syndrome, and, in the latter, as a result of increased ineffective
45 erythropoiesis. Iron overload, especially through the deleterious effects of reactive oxygen species, leads
46 to organ damage that likely impacts the global outcome of patients, especially after hematopoietic stem
47 cell transplantation (HSCT). In these pathological settings (before and after HSCT), oral iron chelation
48 should be considered whenever body iron overload has been firmly established, ideally by magnetic
49 resonance imaging.

50

51

52

KEYWORDS

53 Iron; leukemia; myelodysplastic syndrome; hematopoietic stem cell transplantation; oral chelation;
54 phlebotomy.

55

ABBREVIATIONS

57 ALL: acute lymphoblastic leukemia

58 AML: acute myeloid leukemia

59 DFX: deferasirox

60 HSC: hematopoietic stem cell

61 HSCT: hematopoietic stem cell transplantation

62 LIC: liver iron content

63 LPI: labile plasma iron

- 64 LPS: lipopolysaccharide
- 65 MDS: myelodysplastic syndromes
- 66 MDS-RS: myelodysplastic syndrome with ring sideroblasts
- 67 MSC: mesenchymal stromal cell
- 68 MRI: magnetic resonance imaging
- 69 NTBI: non transferrin-bound iron
- 70 ROS: reactive oxygen species

INTRODUCTION

The crosstalk between iron and hematology is illustrated by the well-known relationship between iron and erythrocytes where iron is required in order to sustain erythrocyte production within the bone marrow. Iron is abundantly found in the blood within these erythrocytes, and released during erythrocyte degradation mainly within the spleen (1). The goal of the present review, beyond examining the role of iron in the erythroid lineage, is to focus on the relationship between iron and hematopoietic cells, with a special emphasis on iron overload and leukemias. Systemic iron overload frequently develops in leukemias, mainly due to transfusion therapy (2-4). Another mechanism, involved in myelodysplastic syndromes (MDS) in particular (hematologic malignancies characterized by a risk of progression to acute myeloid leukemia (AML)), is ineffective erythropoiesis (5). Ineffective erythropoiesis, notably through increased bone marrow production of the hormone erythroferrone (6), reduces hepcidin expression (7), leading to increased digestive absorption of iron and increased splenic release of the iron originating from erythrophagocytosis (8). After a reminder on the physiological role of iron in bone marrow stem cells and mature white blood cells, the following pathological aspects will be considered: the body iron load status in leukemia patients both at diagnosis and during medical care, the negative consequences of iron excess on patient outcome, especially after hematopoietic stem cell transplantation (HSCT), and the clinical interest of removing excessive iron in leukemia patients.

1. IRON: HOMEOSTASIS AND FUNCTIONAL LINKS BETWEEN IRON AND BONE MARROW

1.1. General iron homeostasis

Iron is critical for life due to its major roles in oxygen transport, key enzymatic reactions (such as DNA synthesis or detoxification) and the growth of microorganisms. In vertebrates, iron is abundantly present within red blood cells and in a tiny but functionally essential amount in

the plasma; this plasma iron ensures the delivery of iron to the bone marrow primarily for erythrocyte synthesis and to all living cells (9-11) (Fig. 1). Iron is stored in parenchymal cells (essentially hepatocytes where it is sequestered within ferritin molecules) and in macrophages (mainly splenic macrophages). The only physiological source of iron for the body is alimentary, explaining the risk of iron deficiency when this input is limited. In the case of excessive iron input, either by increased intestinal absorption (such as in hemochromatosis) or by excessive parenteral entry (due to multiple transfusions or excessive iron supplementation), there is no effective possibility for the human body to adapt its excretory pathways, which explains the risk of iron overload. This dual vulnerability to iron deprivation and to iron excess explains that iron homeostasis is very finely regulated, both at the systemic and cellular levels. At the systemic level, the key role belongs to hepcidin, the major hormone regulating iron metabolism. Hepcidin is a small peptide of 25 amino acids, essentially produced by hepatocytes, that decreases the plasma iron concentration. The decreasing effect exerted by hepcidin on the plasma iron level is mediated by the degradation of ferroportin, which is the only known protein to export cellular iron into the plasma. This hepcidin-ferroportin duo acts at two main sites, duodenal enterocytes and the spleen. At the digestive level, through the combined action of ferroportin export and hephaestin oxidation, iron is delivered to plasma transferrin which principally targets the bone marrow in order to produce new red blood cells (see Table 1 for names and symbols of the genes). In the spleen, iron originating from erythrophagocytosis is exported into the plasma through ferroportin, oxidized by ceruloplasmin, bound to transferrin and recycled toward the bone marrow. Many factors can regulate hepcidin expression. Body iron load status is a major regulator: a decrease in iron levels (either plasma transferrin saturation level and/or intrahepatocyte iron load level) leads to lower hepcidin production in order to counteract iron deficiency. The reverse phenomenon occurs in the case of iron overload. Inflammation is also an important regulatory factor, in which the IL6-STAT3 pathway is involved to increase hepcidin production.

The erythroferrone hormone, mainly produced by the bone marrow, is another important regulatory factor (12, 13). Its increased production in the case of dyserythropoiesis leads to the downregulation of hepcidin expression. This decrease in hepcidin production may override the expected increased hepcidin expression in the presence of coexisting iron excess. At the cellular level, iron homeostasis is mainly ensured at a post-transcriptional level by the iron regulatory proteins (IRP). Schematically, in a context of cellular iron deficiency, IRP1 and IRP2 bind to iron regulatory elements (IRE) located in the 5' or 3' untranslated transcribed region (UTR) of the mRNA involved in the entry (TFR1), storage (ferritin) and export of iron (ferroportin). This leads, through different mechanisms (inhibition of translation or stabilization of transcripts), to increased cellular iron entry and decreased cellular iron storage and egress. The reverse effects occur in the case of cellular iron overload, where IRP1 and IRP2 lose their capacity to bind to IRE. Any acquired and/or genetic abnormality in these regulatory processes may lead to iron-related disorders.

Altogether, many of the players involved in iron metabolism are now described at the molecular level. They are transporters, receptors, oxido-reductases, sensors, chelators, regulatory pathway players and hormones. Their interdependency and fine-tuning explain the functional relationship between diverse tissues and iron.

1.2. The functional relationship between iron and bone marrow

There is a very close relationship between iron and bone marrow that can be considered through two reciprocal perspectives. On the one hand, there is an iron flux toward the bone marrow that is physiologically required to sustain crucial hematopoietic functions, and which, when excessive, can exert deleterious effects on hematopoiesis (14-16). On the other hand, the bone marrow not only ensures the delivery into the blood of the different hematological cells involved in iron

metabolism (the erythrocytes in first line), but also plays a key role in the systemic distribution of iron.

1.2.1. From iron to the bone marrow: iron is used by all hematopoietic lineages

1.2.1.1. Iron and bone marrow stem cells: hematopoietic and mesenchymal stromal cells (HSC and MSC)

Iron, through its propensity for producing reactive oxygen species (ROS), exerts a determining role on the fate of HSC (14, 15) and its impact depends on the dose of iron. Low ROS levels are required for HSC renewal. ROS levels also fine-tune HSC differentiation: very low levels can hamper HSC differentiation, whereas increasing ROS levels favor their differentiation. On the contrary, very high ROS levels promote stem cell exhaustion and death by causing cytotoxicity through the binding of ROS to lipid membranes, proteins and DNA, promoting deleterious oxidation of these macromolecules. Excessive iron impairs hematopoiesis by inducing apoptosis and cell cycle arrest (17), and decreases the ratio and clonogenic function of hematopoietic stem and progenitor stem cells (18). Iron also plays a role in other cells in the hematopoietic niche. Iron increases the proliferation of human MSCs and accelerates their entry into S-phase (19). In contrast, excess iron negatively impacts the hematopoietic microenvironment, as shown by the delayed hematopoietic reconstitution observed in mice overloaded by iron-dextran and transplanted with bone marrow from untreated mice (20). Moreover, in MDS patients, iron overload has been shown to promote mitochondrial fragmentation of mesenchymal stromal cells (21).

1.2.1.2. Iron in white cell lineages

A short history... In 1952, CB Laurell wrote that “nobody has investigated whether the white blood cells have any function in iron transportation or hemoglobin breakdown, in spite of the fact that leucocytes have a relatively high iron content” in a seminal review entitled “Plasma iron and iron transport in the organism” (22). Twenty-two years later, Summers and Jacobs (23, 24) showed that monocyte ferritin content was approximately seven times higher than that in lymphocytes or polymorphs in normal subjects. They also reported that the ferritin content increased during anemia of chronic disease in lymphocytes, monocytes and polymorphs. Iron uptake by lymphocytes was also greatly increased during iron deficiency anemia. At the same time, Worwood *et al.* reported that leukemia cells had a markedly increased ferritin content (25). We will now consider the present state of knowledge about iron content, function and impact in white blood cells.

Iron and monocytes-macrophages. Monocytes are known to correspond to circulating macrophages. Iron is required for the differentiation of peripheral blood monocyte precursors into functional macrophages; iron deprivation by desferrioxamine generates macrophages unable to develop a mature phenotype, with an impaired capacity for phagocytosis (23). It is also well known that iron sequestration occurs within macrophages during inflammation. Importantly, interleukin 6 (IL-6), which is produced by macrophages in response to pathogen-associated molecular patterns, activates the STAT3 signaling pathway leading to hyperhepcidinemia, and therefore to the degradation of ferroportin, and eventually to hyposideremia. It has also been shown that inflammation can cause hyposideremia through a hepcidin-independent mechanism involving the transcriptional downregulation of ferroportin (26). Depending on their microenvironment and cooperation with lymphocytes, monocytes polarize into active macrophage populations that are subdivided into activated M1 macrophages exerting proinflammatory and antitumor activities, and into activated M2 macrophages that are immunosuppressive and promote tumor activity. Importantly, iron modulates this macrophage polarization, increasing the M2 phenotype and decreasing the M1 proinflammatory lipopolysaccharide (LPS)-induced response (27). In a mouse model of hemochromatosis (a genetic iron overload disease), attenuated inflammatory responses

to *Salmonella* infection or LPS were observed compared to non-hemochromatosis control mice. This study demonstrates a novel role of iron in the regulation of macrophage IL-6 cytokine mRNA translation (28). This result is coherent with a previous report that showed that TNF α concentrations were decreased in the supernatants of monocytes from hemochromatosis patients (29). Youssef *et al.* (30) reported that, following increased erythrophagocytosis, splenic macrophages undergo ferroptosis and are replaced by circulating monocytes and local cell division. Haschka *et al.* (31) found that classical (CD14⁺, CD16⁻) and intermediate (CD14⁺, CD16⁺) subsets of human monocytes are involved in clearing non-transferrin-bound iron (NTBI) and damaged red blood cells. Therefore monocytes may play a role in limiting iron toxicity in iron overload conditions.

Iron and dendritic cells. Kramer *et al.* showed that differentiation from human peripheral blood monocyte precursors into functional dendritic cells requires iron and is dependent on the expression of the cyclin-dependent kinase inhibitor p21 (32). Iron depletion by the chelator desferrioxamine produced undifferentiated dendritic cells unable to stimulate naive allogeneic T lymphocytes. Olakanmi *et al.* showed that lung myeloid dendritic cells acquire iron from various types of extracellular sources (iron-citrate, iron-transferrin and iron-lactoferrin) (33).

Iron and neutrophils. The positive role of iron on granulopoiesis is suggested by studies in anemic Belgrade (b/b) rats. Indeed, an increased proliferation of granulocytic cells is observed in iron-treated b/b rats (34). Importantly, neutrophils impact iron metabolism during inflammation by secreting lactoferrin (35, 36). Lactoferrin is an iron-binding multifunctional glycoprotein secreted by neutrophils and exocrine glands. During inflammation or infection, the plasma lactoferrin concentration increases through the recruitment of neutrophils (37). The antibacterial and antibiofilm activity of lactoferrin is dependent, although not exclusively, on its iron-binding affinity. However, no evidence has been brought forward regarding a significant impact of lactoferrin on human granulopoiesis (38).

Iron and eosinophils. To our knowledge, the sole interference of iron with the eosinophil lineage involves the role of iron-loaded lactoferrin. Bovine lactoferrin regulates the pathway implicating the CD11b and CD49d integrins and the MIP-1 α and MCP-1 chemokines in granulocyte-macrophage colony-stimulating factor (GM-CSF)-treated human eosinophils (39).

Iron and lymphocytes. Transferrin receptor 1 (TFR1)-mediated iron uptake is essential for lymphocyte proliferation (40). Iron also plays a key role in the differentiation of T lymphocytes. The absence of TFR1 in genetically modified mice leads to a total arrest of T lymphopoiesis at a very early stage of maturation, and the function and impact of iron on B lymphocytes is less pronounced (41). A significant increase in lymphocyte number is observed in iron overload situations such as human *HFE*-related hemochromatosis (42). The number of CD8⁺ T lymphocytes negatively correlates with the severity of iron overload in *HFE*-related hemochromatosis (43). Lymphocytes can also internalize iron through pathways involving non-transferrin-bound iron (NTBI) (44, 45), supporting the view that T lymphocytes may play a protective role against the consequences of iron excess. This result is in accordance with the proposal that T lymphocytes act as a first line protective barrier against the deleterious effects of iron excess (46). The cellular localization of iron was not addressed in this study but the authors suggest that it may be stored within ferritin, in agreement with the demonstration that T lymphocytes are able to synthesize H-ferritin (47).

In summary, all hematopoietic lineages use iron for proliferation and/or differentiation functions, including the white blood cell lineages. The physiological flux of iron toward the bone marrow exerts proliferative and differentiating effects on HSCs and MSCs. An excess of iron within the bone marrow impairs these processes, mainly through an excessive production of ROS. Regarding mature white blood cells, iron is required for the maturation and phagocytotic activity of peripheral monocytes, the differentiation of monocytes into functional dendritic cells, the proliferation of granulocytic cells, and T lymphopoiesis.

1.2.2. From the bone marrow to iron: bone marrow is a prominent player in systemic iron metabolism

Bone marrow, erythrocyte production, and spleen erythrocyte degradation participate in the systemic distribution of iron. Once produced inside the bone marrow, erythrocytes are released into the plasma in order to help oxygenate the body. Circulating red blood cells contain half the total quantity of whole-body iron, *i.e.* approximately 1.5 to 2 g of iron. After 120 days, senescent erythrocytes are degraded within macrophages that release iron from hemoglobin. Iron then re-enters the iron cycle without being excreted.

Bone marrow also plays a critical role in systemic iron regulation by modulating the expression of hepcidin (Fig. 2). The main bone marrow factors that may ultimately regulate hepcidin are GDF15 (growth and differentiation factor 15) (48), TWSG1 (twisted gastrulation BMP signaling modulator 1) (49), and the hormone erythroferrone (encoded by the gene *ERFE*) (6, 7, 12). During dyserythropoiesis, as seen for instance in thalassemia major or intermedia (50-52) or in MDS (5, 53), those factors secreted by the bone marrow may negatively impact hepcidin synthesis, leading to hepcidin deficiency and, in turn, to hypersideremia and subsequently body iron overload (54-56), even prior to any transfusion. Bair *et al.* (57) showed that allogeneic T-replete stem cell transplantation alters iron homeostasis in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, by downregulating liver hepcidin synthesis ahead of upregulating duodenal ferroportin .

In summary, we have shown in this first section that iron is an essential player of bone marrow functions through its implication in proliferation/apoptosis and differentiation of all hematopoietic lineages. In return, the bone marrow impacts the systemic homeostasis of iron by the massive release of iron after erythrophagocytosis, the major source of circulating iron, and by modulating two crucial hormones of iron metabolism, hepcidin and erythroferrone. Having described the normal functional

relationships between iron and the bone marrow, we next explore pathological aspects of this relationship. In the following sections, we report the causative links between iron and leukemia and their clinical implications.

2. IRON STATUS IN LEUKEMIAS

2.1. The most suitable methods to assess body iron load in patients

Evaluating the total body iron load requires the use of reliable tools. In particular, it may not be sufficient to rely exclusively on plasma ferritin levels in light of the numerous non-iron-related factors susceptible to induce hyperferritinemia (58, 59). In leukemia patients, these factors include inflammation (60), the metabolic syndrome (61) and a high ferritin content within leukemic cells (25). It should also be noted that plasma ferritin levels not only depend on the amount of cellular iron deposition but also on the cellular iron distribution. For equivalent cellular iron concentrations, the corresponding plasma ferritin levels are higher for macrophagic (typically transfusional) iron than for parenchymal (hepatocyte) iron, as typically observed in iron excess related to ineffective erythropoiesis (62). The clinician must keep this difference in mind since it may impact the threshold ferritin values used for clinical decision-making when treating iron overload. Combining plasma ferritin and transferrin saturation levels is especially informative, widely available, and cost-effective for the clinician, although both measurements can be affected by inflammation and must be interpreted with caution in this setting. In addition, ferritin can be affected by liver damage, and transferrin saturation fluctuates diurnally and is also affected by cytolysis (63). However useful these iron-related blood parameters may be, the main message is that it is of utmost importance to rely on the direct visualization and quantification of the tissue iron content (especially in the liver and spleen) in order to rigorously assess the body iron load. Non-invasive approaches such as magnetic resonance

imaging (MRI) should be preferentially used (64-67). MRI to determine the liver iron concentration (LIC) has now largely replaced histological assessment by liver biopsy. However, MRI is not widely available nor uniformly done. Bone marrow iron evaluation using MRI, the interest of which has recently been reported for Gaucher disease (68), has not yet been fully evaluated in hematologic malignancies (69). As an illustration of the superiority of MRI evaluation as compared to serum ferritin for body iron load assessment, no hepatic iron overload was found in 13 out of 39 patients who had a serum ferritin level over 1000 ng/mL (70) (71). The bone marrow iron score could be an interesting indicator of secondary iron overload in acute myeloid leukemia patients (72). Dual-energy computed tomography (73) may be a promising technique for the precise assessment of intrahepatic iron distribution in transfusion-dependent patients with hematological malignancies (74).

In summary, the assessment of body iron stores is a two-step process. First, together with the hemoglobin level, the reticulocyte count, red blood cell morphology, serum ferritin and transferrin saturation must be checked. If both the ferritin and transferrin saturation parameters are normal, reflecting an absence of iron excess, no further investigations are required. If they are elevated, and after having checked for possible confounding factors, a direct evaluation of the tissue iron load is required. MRI has currently become the preferred approach given its non-invasive nature, provided it is available and affordable. Among the various methods, the signal intensity ratio method (64, 75) is quite promising as it enables the direct assessment of the hepatic and splenic iron load without requiring specific MRI equipment and provides free interpretation.

2.2. Iron status at diagnosis

It remains difficult to obtain precise data on the body iron status at the time of diagnosis since the iron load check-up is usually done during or after chemotherapy and often from the perspective of HSCT. However, Vag *et al.* (76) reported that LIC measured by MRI was close to normal in eight patients with acute leukemia for whom the determination was performed within 10 days after

therapy initiation. Moreover, the study by Moafi *et al.* (77), based on a histological evaluation of the bone marrow iron stores, reported that, when 30 acute lymphoblastic leukemia (ALL) patients at diagnosis were compared with 30 control subjects, the bone marrow iron score did not differ significantly whereas a significant elevation appeared in leukemia patients after one year of chemotherapy.

Altogether, those limited data suggest that the iron status at diagnosis of acute leukemia is not different from control subjects. However, larger cohorts and prospective studies are required to definitively conclude of this point.

2.3. Body iron load increases in leukemias, mainly due to iron input from blood transfusions

Body iron status has mostly been evaluated while leukemia was being treated. Altogether, the number of studies remains limited when referring to the direct evaluation of body iron stores using appropriate techniques (MRI or histology). Halonen *et al.* reported that 30 children with acute lymphoblastic leukemia (ALL) of whom 19 (63%) had moderate iron overload as assessed by the total iron score (78, 79). Vag *et al.* (76) showed that the mean LIC of 15 children (nine ALL, six AML (acute myeloblastic leukemia)) was significantly increased compared to non-leukemic children. The mean LIC was then correlated with the number of transfusions. Armand *et al.* (80) found that 85% of 48 patients with AML (n=29), ALL (n=11) or MDS (n=8) had a LIC value above the upper limit of normal and, in 42% of patients, significant iron excess corresponded to more than three times the upper limit of normal. Again, iron overload was correlated with the number of transfusions. In Trottier *et al.*'s cohort (4) consisting of 37 leukemia case, eight out of 10 ALL patients and all of the AML patients had an iron overload. A poor relationship was found between LIC and transfusion history. Maximova N *et al.* performed an MRI-based evaluation of multiorgan iron load in pediatric patients who subsequently underwent hematopoietic stem cell transplantation (HSCT) (69). Among these patients, 21 had ALL and eight had AML. Thirteen ALL and all eight AML patients had a significantly elevated

LIC (>2-3 times the upper limit of normal) after HSCT. LIC was not found to be a reliable indicator of total body iron stores as indicated by marked discrepancies between LIC data and the iron estimation in the spleen or bone.

On the whole, for the previously mentioned studies, 49% (91/185) of the ALL or AML patients had significant iron overload before HSCT. In these hematologic malignancies (2, 3), transfusions appeared to be the main cause of the iron burden.

3. IS IRON A PREDISPOSING FACTOR TO LEUKEMIA?

3.1. The potential cellular toxicity of iron

Physiologically, most iron in the body is incorporated within molecular moieties that make it redox-inactive. For instance, iron is bound to plasma transferrin that ensures its transport, and iron is stored within cells in ferritin macromolecules that act as sponges preventing “unbound” or “free” cytosolic iron from being toxic. At the cellular level, a large quantity of iron is incorporated into heme as part of the hemoglobin molecule in erythroid cells, or myoglobin in muscle cells.

However, this protective process can be overridden in iron excess. This holds true when the plasma transferrin saturation with iron is over 45%, with the appearance of non-transferrin-bound iron (NTBI), and especially when the transferrin saturation becomes higher than 75% with the appearance of labile plasma iron (LPI). NTBI is thought to be under the biochemical form of low-molecular weight complexes (such as citrate and acetate), whereas LPI represents the potentially toxic form of circulating iron, defined by its propensity to generate reactive oxygen species (ROS), capable of damaging the membranes of the cells, intracellular organelles and nuclei (17, 81, 82).

In summary, while iron is physiologically redox-inactive, iron excess, characterized by a plasma transferrin saturation with iron over 45%, is toxic for the cells.

3.2. Experimental data converge to indicate the promoting role of iron on leukemia development

The promoting role of iron on tumor development has been explored in numerous types of cancer (83) and the proliferative effect of iron is well documented (84, 85). Iron is also known to favor genetic instability (82). Focusing on leukemia models, the following data were reported. Inoculated L1210 cells (a mouse lymphocytic leukemia cell line) proliferated more in mice injected with iron than in non-iron-treated control animals (86). Further experimental data shed some light on the possible mechanistic impact of iron on tumorigenesis. Iron has been shown to reduce tumor suppressor p53 activity (87); however, two types of data do not fit with a promoting role of iron on tumorigenesis through decreasing p53: on the one hand, iron favors ferroptosis, whereas the mechanism by which p53 could sometimes favor tumorigenesis has been reported to be its suppressing effect on metabolic stress-induced ferroptosis (88); on the other hand, p53 has been shown to decrease the NTBI transporter ZIP14 (also known as SLC39A14) (89), leading to decreased NTBI entry into tumor cells and subsequently to decreased iron-related cell death. The precise role of iron on p53 regulation and its effect needs further clarification. The Eltrombopag effect further illustrates the promoting role of iron on leukemia cell growth. This compound is an oral small-molecule thrombopoietin receptor (TPO-R also known as MLP) agonist used for treating chronic immune thrombocytopenic purpura. However, independently of its TPO-R mediated effect, Eltrombopag is able to inhibit the growth of human and murine leukemia cell lines by inducing differentiation and by slowing cell division through blocking the cell cycle in the G1 phase. Interestingly, Eltrombopag decreased the iron content within leukemic cells in a dose-dependent manner. Preloading cells with iron also resulted in a rescue from the anti-proliferative and differentiation-inducing effects of Eltrombopag, suggesting that the antileukemic effect of Eltrombopag is mediated through intracellular iron content (90). Iron deprivation has been reported to induce monocyte differentiation of AML cells (91) and, more generally, cellular iron-binding may be an interesting approach to counteract cancer through the involvement of various signaling pathways (92). Finally, dihydroartemisinin has been reported to

induce acute myeloid leukemia cell death by inducing ferroptosis through the autophagy-dependent degradation of ferritin (93).

In summary, experimental preclinical data converge to indicate the promoting role of iron on leukemia development, and conversely, the role of iron chelation/deprivation to counteract cancer.

3.3. Is systemic iron overload in non-malignant hematological conditions a predisposition to leukemia?

3.3.1. Lessons from hemochromatosis, the archetype of systemic iron overload

Hemochromatosis is a genetic disorder characterized by diffuse body iron overload caused by increased intestinal iron absorption, which itself is related to hepcidin deficiency (10). *HFE* is by far the most frequently mutated gene found in hemochromatosis, with *C282Y HFE* mostly present in Caucasians. It is still being debated whether or not *HFE*-related genetic susceptibility to hemochromatosis, and therefore iron excess, could favor the development of leukemia. A causative link between the *C282Y HFE* mutation and ALL has not been clearly proven (94, 95) and the same holds true for an association with the haplotype HLA-A3, known to be closely associated with the *HFE* gene (95). However, in a US cohort of 161 childhood ALL cases, Kennedy *et al.* (96) reported that the risk of ALL was not only associated with *C282Y* and *H63D HFE* variants and *S142G TFR1* (transferrin receptor 1) variant, but also to some SNPs in other iron regulatory genes (*SLC11A2* and *TMPRSS6* genes). Although no data were given on the iron status of this cohort, these results strengthen the view that iron overload mediated by genetic variants could contribute to a risk of ALL. No *HFE* association has been reported with AML (97). It should be noted that only exceptional cases associating *HFE*-related hemochromatosis and ALL have been reported (98).

Altogether, a genetic correlation has been found between some variant genes involved in iron metabolism and ALL. The impact of the level of the iron burden is not clearly demonstrated as a cause of those ALL. Moreover, in our opinion, despite the absence of an established link between

hemochromatosis (iron overload) and leukemia, it is important in clinical practice to check *HFE* mutations and, if negative, *non-HFE* mutations, in every leukemic patient with marked iron overload exhibiting the characteristic profile of hepcidin deficiency (increased plasma transferrin saturation associated with parenchymal, especially hepatocyte, iron overload (10, 52)) so as not to miss a coincidentally associated hemochromatosis (10).

3.3.2. Lessons from sickle cell disease and thalassemia, archetypes of secondary iron overload

Sickle cell disease and thalassemia are inherited disorders treated with chronic blood transfusions resulting in diffuse body iron overload. Here again, very little data are available on the promoting role of iron overload in leukemia transformation in these diseases. In sickle cell disease, an over two-fold increase in the risk of leukemia, mostly AML, has been reported in California (99) although it is still unclear if iron overload was one of the risk factors in this study. In thalassemia, only exceptional cases of leukemia have been described, suggesting a coincidental occurrence of these conditions (100).

3.4. Is iron overload a factor favoring the transformation of myelodysplastic syndrome (MDS) into leukemia?

MDS represents a particularly valuable experimental model and clinical situation for studying the role of iron as a leukemia predisposing factor since MDS evolves towards AML transformation in approximately one third of cases (101) (102). MDS encompasses a heterogeneous group of acquired myeloid disorders leading to ineffective hematopoiesis with peripheral cytopenia(s) (103), among which anemia is the most frequent. Patients with MDS can develop iron overload through repeated blood transfusions and/or as a consequence of dyserythropoiesis.

3.4.1. Iron-related oxidative stress in MDS

It is now clear that MDS patients present increased oxidative stress that is further increased by iron overload (104, 105), even in transfusion-independent cases (105). It has been proposed (106) that iron deprivation by low-dose deferasirox can improve erythropoiesis in MDS. It should be noted, however, that iron overload inhibited the proliferation of erythroid progenitor cells in MDS whereas the myeloid compartment was not affected (107). All of the blood marrow cell types in 27 MDS patients exhibited high ROS and low glutathion levels compared to 12 controls, with some correlation with overall survival (108). Interestingly, Ghoti *et al.* found a correlation between ROS and serum ferritin levels in the erythrocytes and platelets of low-grade MDS patients (109). Increased oxidative DNA damage was found in MDS patients both on bone marrow cells (110) (however without correlation with serum ferritin) and on peripheral blood mononuclear cells (111), with a protective effect of oral iron chelation. Importantly, low-risk MDS patients have been reported to present the highest ROS levels (108). Using NHD13 transgenic mice, a murine model of MDS, Chung *et al.* showed that ROS may contribute to the progression of MDS to AML through ineffective DNA repair and increased mutation frequency (112). Given the close relationship between iron and ROS, it is possible that this progression was at least partly related to an iron effect (iron exposure, however, was not used in this experiment).

3.4.2. The impact of dyserythropoiesis and erythroblastic mitochondrial iron overload in MDS to AML transformation

Iron overload due to dyserythropoiesis is mainly found in MDS with ring sideroblasts (MDS-RS), a subgroup characterized by erythroblastic mitochondrial iron overload and a high frequency of somatic mutations in the spliceosome gene *SF3B1* (113). Mean hepcidin levels are heterogeneous across the different MDS subtypes, with the lowest levels in refractory anemia with ring sideroblasts (now classified as MDS-RS with single dysplasia), which present the highest plasma NTBI levels (114-116). Thus, MDS-RS patients have inappropriately low hepcidin levels, a typical feature of iron-

loading anemia (117). Most patients with MDS-RS with single dysplasia are stratified into the lower-risk groups by the revised IPSS (118), pointing out that abnormal mitochondrial iron accumulation may not be a strong factor favoring leukemic transformation.

3.4.3. The impact of transfusional systemic iron overload in MDS to AML transformation

It has been reported that chronic red blood cell transfusions induce an iron overload that impacts the survival of MDS patients (119). In a retrospective study of 467 MDS patients, the leukemia-free survival of transfusion-dependent patients was significantly inferior to that of patients not requiring transfusions, raising the possibility that transfusional iron overload may increase the risk of AML transformation to leukemia (120). However, in a recent Brazilian study, hepatic iron overload, measured by MRI and found in two-thirds of transfused and non-transfused MDS patients, was associated with a lower overall survival, but was not correlated with an increased risk of AML transformation (121). These results should nevertheless be considered in the light of the small cohort size and the heterogeneous clinical status of the patients.

Although clinical data converge to indicate that blood transfusion dependency and an increasing number of transfusions favor shorter overall survival and increase leukemic transformation in MDS patients, it remains difficult to ascertain that these deleterious effects are related to iron overload itself (5). Limiting and confounding factors may include: i) the fact that transfusion dependency could reflect the overall disease severity; ii) the impact of comorbidities that are frequent in these elderly patients; iii) the almost exclusive use of plasma iron parameters (especially ferritin levels) to estimate body iron excess, which does not consistently reflect the iron store (as discussed in 2.1); and iv) the risk of selection bias related to the possible proposal of chelation therapy to patients with a better prognosis. Evaluating the impact of iron depletion by chelation therapy represents a “reverse” approach to understanding the effect of iron excess on MDS to AML transformation. In this regard, the repeatedly-found beneficial effect of iron chelation therapy (106, 122-126) represents an

important argument in favor of iron overload being responsible for promoting AML. In particular, the TELESTO trial by Angelucci *et al.* (127), which is the sole prospective study randomizing deferasirox vs. placebo in low-risk MDS patients, reports a favorable effect of iron chelation on event-free survival, the rate of cardiac and hepatic events and the transformation to AML. However, it should be kept in mind that part of the beneficial effect of the iron chelator deferasirox may be due not only to iron chelation, but to well-documented associated hematopoietic effects (106, 125, 128-134). Finally, regarding the specific effect of iron chelation on AML transformation, the Spanish Iron2 study (126) identified a beneficial effect, although the German registry did not (123).

In summary, while systemic iron overload observed in hemochromatosis and sickle cell disease is not clearly shown as a predisposing condition to leukemia, data are clearer for MDS. Some experimental studies suggest that iron may be a factor facilitating MDS to AML transformation, and bioclinical data show that there is an increase in ROS production in MDS likely causing oxidative stress, including oxidative DNA damage. Clinical data are still lacking, however, to firmly establish the causal relationship between iron overload and leukemia transformation in MDS.

4. THERAPEUTIC ASPECTS RELATED TO IRON OVERLOAD IN LEUKEMIA

4.1. Leukemia treatment and body iron burden

4.1.1. The impact of chemotherapy on iron metabolism: the transient appearance of NTBI

Chemotherapy impacts iron metabolism through two mechanisms. The first one is that chemotherapy causes iron excess when red blood cell transfusions are needed to counteract chemotherapy-related anemia. A high amount of iron bound to hemoglobin is brought together

with massive erythrocyte supplementation. This iron, released from the erythrocytes during erythrophagocytosis, will not be extracted out of the body since no specific iron excretion exists, and will be stored within the organism. This corresponds to a net addition of iron. Another mechanism is that chemotherapy favors the appearance of plasma NTBI. Harrison P *et al.* were the first to report the presence of NTBI during chemotherapy, often concomitant with neutropenia (135). In 23 out of 25 patients, labile plasma iron (LPI) levels increased 48 hours after the start of conditioning pre-autologous HSCT, with a peak before cell infusion and a return to the normal range at engraftment (136, 137). Studying a cohort of 30 patients with acute leukemia (16 AML and 14 ALL), Belotti *et al.* (138) showed that this peak of NTBI was found for all subsequent high-dose chemotherapy courses. The appearance of NTBI during chemotherapy may be essentially due to the massive iron release from the degradation of hemoglobinized bone marrow cells leading to elevated transferrin saturation (139). The presence of NTBI can also be explained on the one hand by a decrease in NTBI uptake by the erythroid cells, given that such uptake has been demonstrated in rat erythroid cells (140). Furthermore, it could be related to hypohepcidinemia due to the absence of erythropoiesis. These different mechanisms can act simultaneously. Finally, high NTBI levels were associated with a higher risk of sepsis (138). It should be noted that susceptibility to infection may be, by itself, an important factor in terms of the survival of patients with leukemia undergoing chemotherapy.

As a whole, chemotherapy causes iron excess when red blood cell transfusions are provided and favors the appearance of plasma NTBI.

4.1.2. The prognostic impact of body iron burden on hematopoietic stem cell transplantation (HSCT)

Numerous studies have concluded, overall, that high serum ferritin levels prior to HSCT are a predictive factor of poor prognosis both in terms of morbidity and mortality. However, as previously

mentioned, hyperferritinemia clearly does not only reflect body iron overload, as this is notably an inflammation marker (see reviews by Moukalled *et al.* (101), Isidori *et al.* (15); Leitch *et al.* (141), Wang *et al.* (142), and Bertoli *et al.* (60)). This is why, in the present review, only studies using a direct assessment, by MRI or histological studies, of the tissue iron concentration will be considered.

A meta-analysis performed by Armand *et al.* (143) of four prospective studies (144) (4, 145, 146), involving 144 AML, 90 ALL and approximately 50 MDS patients, concluded that iron overload was not related to either overall survival or to non-relapse-mortality. However, one of the four studies (145) was not in agreement with the other three, and meta-analysis bias due to a sample size issue could not be totally excluded. Primarily, Wermke *et al.* (147) coordinated the first prospective, German multicenter observational study (the ALLIVE study) assessing the relevance of pretransplantation body iron overload measured by serum ferritin, transfusion burden, enhanced LPI (defined as biologically active iron) and LIC (determined by MRI) in a cohort of hematopoietic malignancies (92 AML and 20 MDS patients) undergoing HSCT. The results indicated that LIC values more than three times the upper limit of normal were significantly associated with increased non-relapse mortality. It is still a possibility that this impact could be restricted to patients having undergone a reduced-intensity conditioning regimen (this case concerns 83% of the studied patients). Moreover, the ALLIVE study showed a significantly increased incidence of non-relapse mortality in patients exhibiting a raised baseline enhanced-NTBI concentration. Moafi *et al.* (77) concluded that high levels of bone marrow iron were associated with a poor response to treatment and to the risk of relapse.

To summarize, body iron overload assessed by direct methods has a predictive value for poor survival after HSCT. However, the predictive value of increased serum ferritin levels, which reflect not only body iron excess but also other mechanisms, of which the foremost is inflammation, may be stronger.

4.2. The impact of iron removal during leukemia treatment

4.2.1. Iron chelation

We will focus on the results obtained using oral iron chelation, especially deferasirox (DFX). Sivgin *et al.* (148) retrospectively investigated 80 patients including 45 AML and 18 ALL patients for whom the pretransplant serum ferritin levels were ≥ 1000 ng/mL. Thirty-seven patients were given DFX and compared to 26 patients who were phlebotomized due to DFX side effects or compliance problems. Overall survival and disease-free survival were significantly better in the DFX group. The first prospective multicenter clinical trial of DFX in adult allogeneic HSCT was carried out in Spain (149). Thirty patients (including 17 AML patients and one ALL patient), with transfusional iron overload (serum ferritin ≥ 1000 ng/mL or ≥ 20 units of packed red blood cells; the LIC assessment was assessed by MRI, depending on equipment availability) received DFX at a starting dose of 10 mg/kg for 52 weeks or until the serum ferritin level was less than 400 ng/mL on two consecutive occasions. There were no severe drug-related adverse events. A significant reduction in ferritinemia was observed from baseline to 52 weeks (1444 to 755 ng/mL) in the intent-to-treat population. LIC was also significantly reduced for the seven patients for whom basal and final LIC (at 52 weeks) could be obtained. The multicenter German study (DE02) (150) assessed the safety and efficacy of DFX in 76 recipients of allogeneic HSCT (comprising 52 AML) who started at a dose of 10 mg/kg with an escalating design up to 20 mg/kg. The median exposure was 330 days. Seventy-one percent of the patients experienced drug-related adverse events (increased blood creatinine, nausea and abdominal discomfort) leading to occasional discontinuation. The median compliance rate was > 80%. A significant decline in serum ferritin was observed (from 2045 to 957 ng/mL) and a negative iron balance was obtained in 84% of patients.

In summary, these studies indicate that DFX is effective for iron chelation therapy after HSCT, with a manageable safety profile. Gastrointestinal side effects may be reduced with the new DFX film-coated tablet formulation (151, 152).

4.2.2. Phlebotomy

Iron removal by phlebotomy is the alternative to iron chelation for therapeutic iron removal. As to the impact of phlebotomies in leukemia patients, most studies have involved patients after allogeneic HSCT. We will focus here on those studies that used a direct evaluation of tissue iron load by liver biopsy (153, 154) or imaging techniques (MRI (155) and, in one study, SQUID (superconducting quantum interference device) (156)). All of the studies converged to conclude that phlebotomy was a safe and well-tolerated procedure. A significant reduction in the liver iron concentration (and serum ferritin) was obtained. A single retrospective study reported that DFX was more effective on iron excess than phlebotomy. However, only serum ferritin levels were evaluated (148).

On the whole, further clinical studies should be carried out to ascertain if the long-term prognosis after HSCT is favorably influenced by decreasing iron excess, through chelation or phlebotomy. Irrespective of the therapeutic method, it should be emphasized that it is highly recommended to avoid foods containing high amounts of iron since this is a natural and cheap way to counteract intestinal iron absorption.

CONCLUSION

Close functional interactions exist physiologically between iron and bone marrow that concern the leukocyte lineage as well as the erythroid cells. From a pathological point of view, iron acts as a co-carcinogenic factor that experimentally promotes leukemia cell growth, whereas clinical data promoting the role of iron in MDS transformation is still under debate. Body iron overload, best

assessed by direct MRI quantification, is usually not increased at the time of leukemia diagnosis; it increases significantly during medical care, especially due to multiple transfusions. Iron overload, notably through the damaging effects of NTBI, which is more likely to appear in the plasma with chemotherapy, significantly contributes to a poor prognosis after HSCT. Hyperferritinemia only partially reflects excess iron in the body but seems to be an interesting prognostic factor since it also occurs in inflammation. Iron removal, mostly by oral chelation, must become the standard of care whenever significant body iron overload has been firmly established.

FUTURE CONSIDERATIONS

In our opinion, increased awareness of the importance of diagnosing body iron excess in leukemia patients remains a key objective. Further clinical trials evaluating the long-term prognostic effect of iron removal by oral chelation are warranted, in principle, but may raise practical difficulties for recruiting patients. Strategies to target iron removal from specific tissues should be considered.

PRACTICE POINTS

- Iron experimentally promotes leukemia cell growth; however, clinically, the promoting role of iron overload in the transformation of MDS into leukemia is still being debated.
- The assessment of body iron status in leukemia patients requires the direct visualization and quantification of iron excess, especially by magnetic resonance imaging (MRI).
- Iron overload, mainly due to transfusions, is likely to contribute to a poor prognosis after hematopoietic stem cell transplantation.
- Hyperferritinemia is an interesting overall indicator of a poor prognosis; this parameter reflects the inflammatory status and, albeit partially, the body iron burden.
- Iron removal by oral chelation or phlebotomies is well tolerated and acts efficient on the body iron burden; its favorable effect on the long-term prognosis is uncertain.

RESEARCH AGENDA

- Further clinical trials investigating the impact of iron on MDS transformation, with appropriate measurement and follow-up of iron burden.

- Exploration of the promoting role of iron in the development of myelodysplastic/myeloproliferative syndromes from hematopoietic stem cells especially by using appropriate transgenic mouse models.

CONFLICT OF INTEREST

PB has been an occasional consultant and member of advisory board for Novartis. No links of interest for the other authors in the frame of the present article.

- 664 1. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. *Cell*.
665 2017;168(3):344-61.
- 666 2. Paananen P, Arola MO, Pelliniemi TT, Salmi TT, Lahteenmaki PM. Evaluation of the effects of
667 different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia. *J*
668 *Pediatr Hematol Oncol*. 2009;31(10):745-9.
- 669 3. Eng J, Fish JD. Insidious iron burden in pediatric patients with acute lymphoblastic leukemia.
670 *Pediatr Blood Cancer*. 2011;56(3):368-71.
- 671 4. Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS. Association of iron overload with allogeneic
672 hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver
673 iron content. *Blood*. 2013;122(9):1678-84.
- 674 5. Gattermann N. Iron overload in myelodysplastic syndromes (MDS). *Int J Hematol*. 2018;107(1):55-
675 63.
- 676 6. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. *Blood*.
677 2014;124(4):479-82.
- 678 7. Miura S, Kobune M, Horiguchi H, Kikuchi S, Iyama S, Murase K, et al. EPO-R+ myelodysplastic cells
679 with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells.
680 *Blood Cells Mol Dis*. 2019;78:1-8.
- 681 8. Ganz T. Hepcidin and iron regulation, 10 years later. *Blood*. 2011;117(17):4425-33.
- 682 9. Brissot P, Loreal O. Iron metabolism and related genetic diseases: A cleared land, keeping
683 mysteries. *J Hepatol*. 2016;64(2):505-15.
- 684 10. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loreal O. Haemochromatosis. *Nat*
685 *Rev Dis Primers*. 2018;4:18016.
- 686 11. Coffey R, Ganz T. Iron homeostasis: An anthropocentric perspective. *J Biol Chem*.
687 2017;292(31):12727-34.
- 688 12. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an
689 erythroid regulator of iron metabolism. *Nat Genet*. 2014;46(7):678-84.
- 690 13. Ganz T. Erythropoietic regulators of iron metabolism. *Free Radic Biol Med*. 2019;133:69-74.
- 691 14. Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. *Blood Rev*.
692 2018;32(1):29-35.
- 693 15. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity - Its effect on the
694 bone marrow. *Blood Rev*. 2018.
- 695 16. Jin X, He X, Cao X, Xu P, Xing Y, Sui S, et al. Iron overload impairs normal hematopoietic stem and
696 progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice.
697 *Haematologica*. 2018;103(10):1627-34.
- 698 17. Lu W, Zhao M, Rajbhandary S, Xie F, Chai X, Mu J, et al. Free iron catalyzes oxidative damage to
699 hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload
700 patients. *Eur J Haematol*. 2013;91(3):249-61.
- 701 18. Chai X, Li D, Cao X, Zhang Y, Mu J, Lu W, et al. ROS-mediated iron overload injures the
702 hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. *Sci Rep*.
703 2015;5:10181.
- 704 19. Borriello A, Caldarelli I, Speranza MC, Scianguetta S, Tramontano A, Bencivenga D, et al. Iron
705 overload enhances human mesenchymal stromal cell growth and hampers matrix calcification. *Biochim*
706 *Biophys Acta*. 2016;1860(6):1211-23.
- 707 20. Okabe H, Suzuki T, Uehara E, Ueda M, Nagai T, Ozawa K. The bone marrow hematopoietic
708 microenvironment is impaired in iron-overloaded mice. *Eur J Haematol*. 2014;93(2):118-28.
- 709 21. Zheng Q, Zhao Y, Guo J, Zhao S, Fei C, Xiao C, et al. Iron overload promotes mitochondrial
710 fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation
711 of the AMPK/MFF/Drp1 pathway. *Cell Death Dis*. 2018;9(5):515.

712 22. Laurell CB. Plasma iron and the transport of iron in the organism. *Pharmacol Rev.* 1952;4(4):371-
713 95.

714 23. Summers M, Worwood M, Jacobs A. Ferritin in normal erythrocytes, lymphocytes, polymorphs,
715 and monocytes. *Br J Haematol.* 1974;28(1):19-26.

716 24. Summers MR, Jacobs A. Iron uptake and ferritin synthesis by peripheral blood leucocytes from
717 normal subjects and patients with iron deficiency and the anaemia of chronic disease. *Br J Haematol.*
718 1976;34(2):221-9.

719 25. Worwood M, Summers M, Miller F, Jacobs A, Whittaker JA. Ferritin in blood cells from normal
720 subjects and patients with leukaemia. *Br J Haematol.* 1974;28(1):27-35.

721 26. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, et al. A novel inflammatory pathway
722 mediating rapid hepcidin-independent hypoferremia. *Blood.* 2015;125(14):2265-75.

723 27. Agoro R, Taleb M, Quesniaux VFJ, Mura C. Cell iron status influences macrophage polarization.
724 *PLoS One.* 2018;13(5):e0196921.

725 28. Wang L, Azad N, Kongkaneramt L, Chen F, Lu Y, Jiang BH, et al. The Fas death signaling pathway
726 connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. *J Immunol.*
727 2008;180(5):3072-80.

728 29. Gordeuk VR, Ballou S, Lozanski G, Brittenham GM. Decreased concentrations of tumor necrosis
729 factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis. *Blood.*
730 1992;79(7):1855-60.

731 30. Youssef LA, Rebbaa A, Pampou S, Weisberg SP, Stockwell BR, Hod EA, et al. Increased
732 erythrophagocytosis induces ferroptosis in red pulp macrophages in a mouse model of transfusion. *Blood.*
733 2018;131(23):2581-93.

734 31. Haschka D, Petzer V, Kocher F, Tschurtschenthaler C, Schaefer B, Seifert M, Sopper S, Sonnweber
735 T, Feistritz C, Arvedson TL, Zoller H, Stauder R, Theurl I, Weiss G, Tymoszyk P. Classical and intermediate
736 monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. *JCI Insight.* 2019;8;4(8).

737 32. Kramer JL, Baltathakis I, Alcantara OS, Boldt DH. Differentiation of functional dendritic cells and
738 macrophages from human peripheral blood monocyte precursors is dependent on expression of p21
739 (WAF1/CIP1) and requires iron. *Br J Haematol.* 2002;117(3):727-34.

740 33. Olakanmi O, Kesavalu B, Abdalla MY, Britigan BE. Iron acquisition by Mycobacterium tuberculosis
741 residing within myeloid dendritic cells. *Microb Pathog.* 2013;65:21-8.

742 34. Stojanovic N, Jovicic G, Basara N, Pavlovic-Kentera V. Granulopoiesis in anemic Belgrade laboratory
743 (b/b) rats. *Exp Hematol.* 1990;18(5):379-83.

744 35. Borregaard N. Neutrophils, from marrow to microbes. *Immunity.* 2010;33(5):657-70.

745 36. Kolaczowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. *Nat*
746 *Rev Immunol.* 2013;13(3):159-75.

747 37. Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: A Natural Glycoprotein Involved
748 in Iron and Inflammatory Homeostasis. *Int J Mol Sci.* 2017;18(9).

749 38. Delforge A, Stryckmans P, Prieels JP, Bieva C, Ronge-Collard E, Schlusberg J, et al. Lactoferrin:
750 its role as a regulator of human granulopoiesis? *Ann N Y Acad Sci.* 1985;459:85-96.

751 39. Curran CS, Bertics PJ. Lactoferrin regulates an axis involving CD11b and CD49d integrins and the
752 chemokines MIP-1alpha and MCP-1 in GM-CSF-treated human primary eosinophils. *J Interferon Cytokine*
753 *Res.* 2012;32(10):450-61.

754 40. Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T
755 lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. *Proc Natl*
756 *Acad Sci U S A.* 1983;80(11):3494-8.

757 41. Ned RM, Swat W, Andrews NC. Transferrin receptor 1 is differentially required in lymphocyte
758 development. *Blood.* 2003;102(10):3711-8.

759 42. Barton JC, Wiener HW, Acton RT, Go RC. Total blood lymphocyte counts in hemochromatosis
760 probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles
761 and haplotypes. *BMC Blood Disord.* 2005;5:5.

762 43. Cruz E, Melo G, Lacerda R, Almeida S, Porto G. The CD8+ T-lymphocyte profile as a modifier of iron
763 overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y
764 homozygous subjects. *Blood Cells Mol Dis.* 2006;37(1):33-9.

765 44. Arezes J, Costa M, Vieira I, Dias V, Kong XL, Fernandes R, et al. Non-transferrin-bound iron (NTBI)
766 uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species. *PLoS*
767 *One.* 2013;8(11):e79870.

768 45. Pinto JP, Arezes J, Dias V, Oliveira S, Vieira I, Costa M, et al. Physiological implications of NTBI
769 uptake by T lymphocytes. *Front Pharmacol.* 2014;5:24.

770 46. Porto G, De Sousa M. Iron overload and immunity. *World J Gastroenterol.* 2007;13(35):4707-15.

771 47. Dorner MH, Silverstone A, Nishiya K, de Sostoa A, Munn G, de Sousa M. Ferritin synthesis by
772 human T lymphocytes. *Science.* 1980;209(4460):1019-21.

773 48. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia
774 suppress expression of the iron regulatory protein hepcidin. *Nat Med.* 2007;13(9):1096-101.

775 49. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1
776 as a second novel erythroid regulator of hepcidin expression in murine and human cells. *Blood.*
777 2009;114(1):181-6.

778 50. Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. *Adv Hematol.*
779 2010;2010:358283.

780 51. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading
781 anaemias. *Br J Haematol.* 2016;172(4):512-23.

782 52. Brissot P, Troadec MB, Loreal O, Brissot E. Pathophysiology and classification of iron overload
783 diseases; update 2018. *Transfus Clin Biol.* 2018.

784 53. Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S. Unraveling the mechanisms behind
785 iron overload and ineffective hematopoiesis in myelodysplastic syndromes. *Leuk Res.* 2017;62:108-15.

786 54. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific
787 gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during
788 iron overload. *J Biol Chem.* 2001;276(11):7811-9.

789 55. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene
790 expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proc*
791 *Natl Acad Sci U S A.* 2001;98(15):8780-5.

792 56. Ganz T. Systemic iron homeostasis. *Physiol Rev.* 2013;93(4):1721-41.

793 57. Bair S, Spaulding E, Parkkinen J, Shulman HM, Lesnikov V, Beauchamp M, et al. Transplantation of
794 allogeneic T cells alters iron homeostasis in NOD/SCID mice. *Blood.* 2009;113(8):1841-4.

795 58. Brissot P. Comment je traite une hyperferritinémie. *Hématologie.* 2015;21:139-45.

796 59. Brissot E, Savani BN, Mohty M. Management of high ferritin in long-term survivors after
797 hematopoietic stem cell transplantation. *Semin Hematol.* 2012;49(1):35-42.

798 60. Bertoli S, Paubelle E, Berard E, Saland E, Thomas X, Tavitian S, et al. Ferritin heavy/light chain
799 (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute
800 myeloid leukemia. *Eur J Haematol.* 2019;102(2):131-42.

801 61. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic
802 Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive
803 Practice Recommendations from the CIBMTR and EBMT. *Biol Blood Marrow Transplant.* 2016;22(8):1493-
804 503.

805 62. Musallam KM, Taher AT. Iron-chelating therapy for transfusional iron overload. *N Engl J Med.*
806 2011;364(15):1476.

807 63. Brissot P. BE. Comment j'interprète la saturation de la transferrine. *Hématologie.* 2017;23:406-
808 12.

809 64. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Non-invasive assessment of
810 hepatic iron stores by MRI. *Lancet.* 2004;363(9406):357-62.

811 65. Wood JC. Estimating tissue iron burden: current status and future prospects. *Br J Haematol.*
812 2015;170(1):15-28.

66. St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S, et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. *Magn Reson Med*. 2014;71(6):2215-23.
67. Rose C, Vandevenne P, Bourgeois E, Cambier N, Ernst O. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. *Eur J Haematol*. 2006;77(2):145-9.
68. Regenboog M, Bohte AE, Akkerman EM, Stoker J, Hollak CEM. Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment. *Br J Haematol*. 2017;179(4):635-47.
69. Maximova N, Gregori M, Boz G, Simeone R, Zanon D, Schillani G, et al. MRI-based evaluation of multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. *Oncotarget*. 2017;8(45):79650-61.
70. Olcay L, Hazirolan T, Yildirmak Y, Erdemli E, Terzi YK, Arda K, et al. Biochemical, radiologic, ultrastructural, and genetic evaluation of iron overload in acute leukemia and iron-chelation therapy. *J Pediatr Hematol Oncol*. 2014;36(4):281-92.
71. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. *Biol Blood Marrow Transplant*. 2010;16(6):832-7.
72. Hoeks M, van der Pol M, Middelburg R, Evers D, van Kraaij M, Zwaginga JJ. Bone marrow iron score as an indicator for secondary iron overload in acute myeloid leukemia patients. *Eur J Haematol*. 2018.
73. Goo HW, Goo JM. Dual-Energy CT: New Horizon in Medical Imaging. *Korean J Radiol*. 2017;18(4):555-69.
74. Kobayashi H, Yoshimura N, Uemura S, Katagiri T, Tanaka T, Ushiki T, et al. Heterogeneity of intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological malignancies. *Leuk Res*. 2018;70:41-4.
75. d'Assignies G, Paisant A, Bardou-Jacquet E, Boulic A, Bannier E, Laine F, et al. Non-invasive measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against biopsy. *Eur Radiol*. 2018;28(5):2022-30.
76. Vag T, Kentouche K, Krumbein I, Reichenbach JR, Lopatta E, Renz DM, et al. Noninvasive measurement of liver iron concentration at MRI in children with acute leukemia: initial results. *Pediatr Radiol*. 2011;41(8):980-4.
77. Moafi A, Ziaie M, Abedi M, Rahgozar S, Reisi N, Nematollahi P, et al. The relationship between iron bone marrow stores and response to treatment in pediatric acute lymphoblastic leukemia. *Medicine (Baltimore)*. 2017;96(44):e8511.
78. Halonen P, Mattila J, Suominen P, Ruuska T, Salo MK, Makiperna A. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. *Pediatrics*. 2003;111(1):91-6.
79. Deugnier Y, Turlin B. Pathology of hepatic iron overload. *Semin Liver Dis*. 2011;31(3):260-71.
80. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. *Biol Blood Marrow Transplant*. 2011;17(6):852-60.
81. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: A key role in iron overload and iron toxicity. *Biochim Biophys Acta*. 2012;1820:403-10.
82. Troadec MB, Loreal O, Brissot P. The interaction of iron and the genome: For better and for worse. *Mutat Res*. 2017;774:25-32.
83. Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. *Crit Rev Oncol Hematol*. 2014;89(1):1-15.
84. Chenoufi N, Drenou B, Loreal O, Pigeon C, Brissot P, Lescoat G. Antiproliferative effect of deferiprone on the Hep G2 cell line. *Biochem Pharmacol*. 1998;56(4):431-7.
85. Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, et al. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. *Biomaterials*. 2010;23(2):231-45.

86. Bergeron RJ, Streiff RR, Elliott GT. Influence of iron on in vivo proliferation and lethality of L1210 cells. *J Nutr.* 1985;115(3):369-74.
87. Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. *Cell Rep.* 2014;7(1):180-93.
88. Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. *Cell Rep.* 2018;22(3):569-75.
89. Zhao N, Zhang AS, Wortham AM, Jue S, Knutson MD, Enns CA. The Tumor Suppressor, P53, Decreases the Metal Transporter, ZIP14. *Nutrients.* 2017;9(12).
90. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. *Blood.* 2012;120(2):386-94.
91. Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. *J Exp Med.* 2010;207(4):731-50.
92. Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS, Richardson DR. Targeting cancer by binding iron: Dissecting cellular signaling pathways. *Oncotarget.* 2015;6(22):18748-79.
93. Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. *Free Radic Biol Med.* 2019;131:356-69.
94. Dorak MT, Mackay RK, Relton CL, Worwood M, Parker L, Hall AG. Hereditary hemochromatosis gene (HFE) variants are associated with birth weight and childhood leukemia risk. *Pediatr Blood Cancer.* 2009;53(7):1242-8.
95. Rodriguez-Lopez R, Donoso M, Fernandez-Cavada M, Gonzalez LM, Margallo A, Corral C, et al. Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility to acute lymphoblastic leukemia. *Gene.* 2013;514(1):31-5.
96. Kennedy AE, Kamdar KY, Lupo PJ, Okcu MF, Scheurer ME, Baum MK, et al. Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes. *Leuk Res.* 2014;38(9):1055-60.
97. Dorak MT, Burnett AK, Worwood M. HFE gene mutations in susceptibility to childhood leukemia: HuGE review. *Genet Med.* 2005;7(3):159-68.
98. Balagtas JM, Dahl GV. Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis. *Pediatr Blood Cancer.* 2012;58(1):101-3.
99. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. *Blood.* 2017;130(13):1597-9.
100. Alavi S, Safari A, Sadeghi E, Amiri S. Hematological malignancies complicating beta-thalassemia syndromes: a single center experience. *Blood Res.* 2013;48(2):149-51.
101. Moukalled NM, El Rassi FA, Temraz SN, Taher AT. Iron overload in patients with myelodysplastic syndromes: An updated overview. *Cancer.* 2018 ; 124 (20) ; 3979-3989.
102. Hasserjian RP. Myelodysplastic Syndrome Updated. *Pathobiology.* 2018:1-7.
103. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood.* 2016;127(20):2391-405.
104. de Souza GF, Barbosa MC, Santos TE, Carvalho TM, de Freitas RM, Martins MR, et al. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. *J Clin Pathol.* 2013;66(11):996-8.
105. Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. *J Int Med Res.* 2011;39(5):1941-5.
106. Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, et al. Reactive oxygen species levels control NF-kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. *Oncotarget.* 2017;8(62):105510-24.

107. Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietzschke F, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. *Leuk Res.* 2013;37(3):327-32.
108. Goncalves AC, Cortesao E, Oliveiros B, Alves V, Espadana AI, Rito L, et al. Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study. *Free Radic Res.* 2015;49(9):1081-94.
109. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. *Eur J Haematol.* 2007;79(6):463-7.
110. Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. *Leuk Res.* 2009;33(2):340-3.
111. Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. *Free Radic Biol Med.* 2012;53(4):643-8.
112. Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. *Leuk Res.* 2014;38(1):95-102.
113. Malcovati L, Cazzola M. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. *Br J Haematol.* 2016;174(6):847-58.
114. Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Delilieri GL, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? *Hematol J.* 2000;1(3):153-8.
115. Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Heparin levels and their determinants in different types of myelodysplastic syndromes. *PLoS One.* 2011;6(8):e23109.
116. Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. *Haematologica.* 2019;104(3):497-504.
117. Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Galli A, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. *Haematologica.* 2013;98(3):420-3.
118. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". *Am J Hematol.* 2019.
119. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglini E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. *J Clin Oncol.* 2005;23(30):7594-603.
120. Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, et al. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. *Leuk Res.* 2018;74:21-41.
121. Mantovani LF, Santos FPS, Perini GF, Nascimento CMB, Silva LP, Wroclawski CK, et al. Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodysplastic syndrome: A cross-sectional study. *Leuk Res.* 2019;76:53-7.
122. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. *Leuk Res.* 2007;31 Suppl 3:S7-9.
123. Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry. *Leuk Res.* 2012;36(8):1067-70.
124. Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. *Leuk Res.* 2014;38(5):557-63.
125. Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). *Eur J Haematol.* 2014;92(6):527-36.
126. Remacha AF, Arrizabalaga B, Villegas A, Duran MS, Hermosin L, de Paz R, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. *Ann Hematol.* 2015;94(5):779-87.

968 127. Angelucci E LJ, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox
969 versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS):
970 outcomes from the randomized, double-blind Telesio study. Abstract #234. Presented at the 2018 ASH
971 Annual Meeting, December 1, 2018; San Diego, CA.

972 128. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic
973 responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
974 *Haematologica*. 2012;97(9):1364-71.

975 129. List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, et al. Deferasirox reduces
976 serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic
977 syndrome. *J Clin Oncol*. 2012;30(17):2134-9.

978 130. Molteni A, Riva M, Pellizzari A, Borin L, Freyrie A, Greco R, et al. Hematological improvement
979 during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica
980 Lombarda". *Leuk Res*. 2013;37(10):1233-40.

981 131. Improta S, Villa MR, Volpe A, Lombardi A, Stiuso P, Cantore N, et al. Transfusion-dependent low-
982 risk myelodysplastic patients receiving deferasirox: Long-term follow-up. *Oncol Lett*. 2013;6(6):1774-8.

983 132. Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, et al. Deferasirox improves hematologic and
984 hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional
985 iron overload patients with myelodysplastic syndrome or aplastic anemia. *Transfusion*. 2014;54(6):1542-
986 51.

987 133. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and
988 potential benefit from iron chelation in low-risk myelodysplastic syndrome. *Blood*. 2014;124(6):873-81.

989 134. Shapira S, Raanani P, Samara A, Nagler A, Lubin I, Arber N, et al. Deferasirox selectively induces
990 cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation,
991 induction of ROS, and inhibition of HIF1alpha expression. *Exp Hematol*. 2019;70:55-69 e4.

992 135. Harrison P, Marwah SS, Hughes RT, Bareford D. Non-transferrin bound iron and neutropenia after
993 cytotoxic chemotherapy. *J Clin Pathol*. 1994;47(4):350-2.

994 136. Naoum FA, Esposito BP, Ruiz LP, Ruiz MA, Tanaka PY, Sobreira JT, et al. Assessment of labile plasma
995 iron in patients who undergo hematopoietic stem cell transplantation. *Acta Haematol*. 2014;131(4):222-
996 6.

997 137. Naoum FA, Esposito BP, Cancado RD. Impact of conditioning and engraftment on iron status in
998 hematopoietic stem cell transplantation: Contribution of labile plasma iron. *Hematol Oncol Stem Cell*
999 *Ther*. 2016;9(4):165-7.

1000 138. Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, et al. Non transferrin bound iron (NTBI) in
1001 acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and
1002 potential predictive role in infectious complications. *Leuk Res*. 2015;39(1):88-91.

1003 139. Porter JB, Walter PB, Neumayr LD, Evans P, Bansal S, Garbowski M, et al. Mechanisms of plasma
1004 non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia
1005 with sickle cell and thalassaemia patients. *Br J Haematol*. 2014;167(5):692-6.

1006 140. Morgan EH. Mechanisms of iron transport into rat erythroid cells. *J Cell Physiol*. 2001;186(2):193-
1007 200.

1008 141. anLeitch HA, Fibach E, Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the
1009 setting of hematopoietic stem cell transplantation for hematologic malignancies. *Crit Rev Oncol Hematol*.
1010 2017;113:156-70.

1011 142. Wang Z, Jia M, Zhao H, Cheng Y, Luo Z, Chen Y, et al. Prognostic impact of pretransplantation
1012 hyperferritinemia in adults undergoing allogeneic hematopoietic SCT: a meta-analysis. *Bone Marrow*
1013 *Transplant*. 2014;49(10):1339-40.

1014 143. Armand P, Kim HT, Virtanen JM, Parkkola RK, Itala-Remes MA, Majhail NS, et al. Iron overload in
1015 allogeneic hematopoietic cell transplantation outcome: a meta-analysis. *Biol Blood Marrow Transplant*.
1016 2014;20(8):1248-51.

1017 144. Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, et al. Does iron overload really matter
1018 in stem cell transplantation? *Am J Hematol*. 2012;87(6):569-72.


145. Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schonefeldt C, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. *Clin Cancer Res*. 2012;18(23):6460-8.
146. Virtanen JM, Itala-Remes MA, Remes KJ, Vahlberg T, Saunavaara JP, Sinisalo M, et al. Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. *Eur J Haematol*. 2013;91(1):85-93.
147. Wermke M, Eckoldt J, Gotze KS, Klein SA, Bug G, de Wreede LC, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. *Lancet Haematol*. 2018;5(5):e201-e10.
148. Sivgin S, Baldane S, Akyol G, Keklik M, Kaynar L, Kurnaz F, et al. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. *Transfus Apher Sci*. 2013;49(2):295-301.
149. Vallejo C, Batlle M, Vazquez L, Solano C, Sampol A, Duarte R, et al. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. *Haematologica*. 2014;99(10):1632-7.
150. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, et al. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2016;51(1):89-95.
151. Kattamis A, Aydinok Y, Taher A. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. *Eur J Haematol*. 2018;101(3):272-82.
152. Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, et al. Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. *Am J Hematol*. 2019;94(4):E96-E9.
153. Tomas JF, Pinilla I, Garcia-Buey ML, Garcia A, Figuera A, Gomez-Garcia de Soria VGG, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. *Bone Marrow Transplant*. 2000;26(6):649-55.
154. Kamble RT, Selby GB, Mims M, Kharfan-Dabaja MA, Ozer H, George JN. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2006;12(5):506-10.
155. Kew AK, Clarke S, Ridler A, Burrell S, Edwards JA, Doucette S, et al. A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT. *Bone Marrow Transplant*. 2015;50(3):457-8.
156. Busca A, Falda M, Manzini P, D'Antico S, Valfre A, Locatelli F, et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. *Biol Blood Marrow Transplant*. 2010;16(1):115-22.


FIGURE LEGENDS

FIGURE 1. Systemic iron homeostasis. Plasma iron comes from the duodenum (digestive iron absorption) and the spleen (iron originating from erythrophagocytosis). Once in the plasma, iron is bound to transferrin (TF) and mainly sent to the bone marrow for the production of new red blood cells. The “bone marrow-spleen-bone marrow” cycling process represents, quantitatively, every day, about 20 times the amount of iron coming from digestive absorption. If plasma iron increases, hepcidin production by the liver is increased, leading to decreased activity of ferroportin both at the duodenum and spleen levels, which in turn decreases plasma iron (the reverse regulation occurs in case of decreased plasma iron).

FIGURE 2. Bone marrow and iron metabolism. Due to iron toxicity, malignancy or chemotherapy, the functionality of bone marrow stem cells (BMSC) can be altered, leading, for the erythroid cell lineage, to dyserythropoiesis, which in turn causes an increased production of various factors including GDF15 and the hormone erythroferrone. These factors lead to a decrease in hepcidin production, then to an increase of plasma iron and, through non-transferrin bound iron, to iron deposition into various parenchymal cells (in first line the hepatocytes): it may lead to body iron overload (this iron excess can increase hepcidin but the increasing signal remains dominated by the reverse impact of dyserythropoiesis (and anemia itself)).

Figure 1
Brissot





Gene name and aliases	Gene symbol (Official, others)
aconitase 1, soluble	<i>ACO1</i> ; <i>IRP1</i> ; <i>IREB1</i> ; <i>IREBP</i>
<u>ceruloplasmin</u>	<i>CP</i>
<u>erythroferrone</u>	<i>ERFE</i> , <i>FAM132B</i>
<u>ferritin</u> , heavy polypeptide 1	<i>FTH1</i> ; <i>FTH</i>
<u>ferritin</u> , light polypeptide	<i>FTL</i> ; L-ferritin
<u>ferroportin</u> ; solute carrier family 40 (iron-regulated transporter), member 1	<i>SLC40A1</i> ; <i>IREG1</i> ; <i>MTP1</i> ; <i>SLC11A3</i> ; <i>FPN</i>
hemochromatosis	<i>HFE</i> ; <i>HH</i> ; <i>HFE1</i> ; <i>HLA-H</i>
<u>hepcidin</u> ; human anti-microbial peptide	<i>HAMP</i> ; <i>HEPC</i> ; <i>LEAP1</i>
<u>hephaestin</u>	<i>HEPH</i> ; <i>CPL</i>
iron-responsive element binding protein 2	<i>IREB2</i> ; <i>IRP2</i> ; <i>ACO3</i> ; <i>IRP2AD</i>
thrombopoietin Receptor	<i>MPL</i> , <i>TPO-R</i>
<u>transferrin</u>	<i>TF</i>
<u>transferrin receptor</u>	<i>TFRC</i> ; <i>TFR1</i> ; <i>TFR</i> ; <i>CD71</i>
transferrin receptor 2	<i>TFR2</i>

Table 1 : Principal iron regulatory genes presented in the review, with their multiple gene symbols. We have underlined the names and/or symbols used in the review.